EU OKs Continued Use Of Etifoxine For Anxiety Despite Toxicity Concerns
The European Medicines Agency has also recommended that EU member states go ahead and approve Tiofarma’s midazolam nasal spray Nasolam for convulsive seizures, while a review of a lidocaine/prilocaine product from French firm International Drug Development has been stopped after the applicant withdrew its decentralized marketing authorization application.
You may also be interested in...
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
A coordinated effort will be needed if Africa is to increase its manufacturing capacity and ensure a market for domestically produced vaccines.
Pharma firms in France are facing tougher sanctions from October if they fail to honor their obligations in terms of anticipating and managing potential or actual drug shortages.